BRPI0608309A2 - administração intranasal de agentes ativos ao sistema nervoso central - Google Patents

administração intranasal de agentes ativos ao sistema nervoso central

Info

Publication number
BRPI0608309A2
BRPI0608309A2 BRPI0608309-9A BRPI0608309A BRPI0608309A2 BR PI0608309 A2 BRPI0608309 A2 BR PI0608309A2 BR PI0608309 A BRPI0608309 A BR PI0608309A BR PI0608309 A2 BRPI0608309 A2 BR PI0608309A2
Authority
BR
Brazil
Prior art keywords
nervous system
central nervous
intranasal administration
active agents
polypeptide
Prior art date
Application number
BRPI0608309-9A
Other languages
English (en)
Inventor
Johanna H Bentz
Beth L Hill
Catherine Lucas
William H Frey
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of BRPI0608309A2 publication Critical patent/BRPI0608309A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/086—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being alphaMSH, alpha melanocyte stimulating hormone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)

Abstract

ADMINISTRAçãO INTRANASAL DE AGENTES ATIVOS AO SISTEMA NERVOSO CENTRAL. é fornecido um método para liberar um polipeptídeo para o sistema nervosa central de um mamífero. O método envolve ligar o polipeptideo a um anticorpo ou um fragmento de anticorpo e administrar o polipeptideo de fusão intranasalmente, para a liberação para o sistema nervosa central. São também fornecidos métodos de tratamento, onde uma quantidade terapeuticamente eficaz da composição é liberada para a cavidade nasal de um mamífero.
BRPI0608309-9A 2005-02-23 2006-01-27 administração intranasal de agentes ativos ao sistema nervoso central BRPI0608309A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65580905P 2005-02-23 2005-02-23
PCT/US2006/003110 WO2006091332A2 (en) 2005-02-23 2006-01-27 Intranasal administration of active agents to the central nervous system

Publications (1)

Publication Number Publication Date
BRPI0608309A2 true BRPI0608309A2 (pt) 2009-12-08

Family

ID=36821878

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0608309-9A BRPI0608309A2 (pt) 2005-02-23 2006-01-27 administração intranasal de agentes ativos ao sistema nervoso central

Country Status (12)

Country Link
US (1) US20060188496A1 (pt)
EP (1) EP1853288A2 (pt)
JP (1) JP2008531560A (pt)
KR (1) KR20070110087A (pt)
CN (1) CN101184499B (pt)
AU (1) AU2006217027A1 (pt)
BR (1) BRPI0608309A2 (pt)
CA (1) CA2598666A1 (pt)
HK (1) HK1122723A1 (pt)
MX (1) MX2007010244A (pt)
NZ (1) NZ581205A (pt)
WO (1) WO2006091332A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
US20070093420A1 (en) 2005-08-26 2007-04-26 Yeomans David C Therapy procedure for drug delivery for trigeminal pain
US7790671B2 (en) * 2005-10-07 2010-09-07 Codman & Shurtleff, Inc. Implantable pump for protein delivery for obesity control by drug infusion into the brain
WO2008049897A1 (en) * 2006-10-27 2008-05-02 Ablynx N.V. Intranasal delivery of polypeptides and proteins
DE102007052380A1 (de) * 2007-10-31 2009-05-07 Bitop Ag Osmolythaltige Zubereitungen zur Anwendung bei trockenen Schleimhäuten
DE102008039231A1 (de) 2008-08-22 2010-02-25 Bitop Ag Verwendung von Glucosylglycerol
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
EP2961426B1 (en) 2013-02-26 2019-10-30 Baxalta GmbH Treatment of central nervous system disorders by intranasal administration of immunoglobulin g
WO2014176360A1 (en) * 2013-04-23 2014-10-30 Board Of Regents, The University Of Texas System Methods for reducing acute axonal injury
EP3552624A1 (en) 2013-05-06 2019-10-16 Baxalta Incorporated Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g
EP3804811A1 (en) * 2013-05-13 2021-04-14 Icahn School of Medicine at Mount Sinai Treatment of mood and anxiety disorders
CN105377039A (zh) 2013-05-15 2016-03-02 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
AU2016205225A1 (en) 2015-01-07 2017-08-17 Trigemina, Inc. Magnesium-containing oxytocin formulations and methods of use
JP7201432B2 (ja) * 2015-11-18 2023-01-10 ヘランティス ファーマ ピーエルシー 中枢神経系疾患の鼻腔内治療に使用するためのｃｄｎｆまたはｍａｎｆを含む組成物
EP3452104A1 (en) 2016-04-15 2019-03-13 The Trustees of The University of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
IL264825B (en) * 2016-08-14 2022-08-01 Univ Ramot Exosomes from mesenchymal cells for the treatment of neurological diseases
EP3684938A1 (en) 2017-09-22 2020-07-29 The Trustees of the University of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
WO2020163815A1 (en) * 2019-02-07 2020-08-13 Innomed Technologies, Inc. Ivig treatments for bell's palsy
WO2020177627A1 (zh) * 2019-03-02 2020-09-10 上海一宸医药科技有限公司 一种双特异抗体

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4476116A (en) * 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5856298A (en) * 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
GB9020544D0 (en) * 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
US5830853A (en) * 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US5897858A (en) * 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US7273618B2 (en) * 1998-12-09 2007-09-25 Chiron Corporation Method for administering agents to the central nervous system
EP1137401B1 (en) * 1998-12-09 2005-11-23 Chiron Corporation Administration of neurotrophic agents to the central nervous system
IL144988A0 (en) * 1999-03-03 2002-06-30 Optinose As Nasal delivery device
ATE316982T1 (de) * 1999-08-09 2006-02-15 Lexigen Pharm Corp Mehrere zytokin-antikörper komplexen
US6824780B1 (en) * 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
EP1575499A2 (en) * 2002-06-28 2005-09-21 Centocor, Inc. Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses
US6734427B1 (en) * 2003-02-14 2004-05-11 United Microelectronics Corp. TEM/SEM sample preparation

Also Published As

Publication number Publication date
NZ581205A (en) 2011-06-30
JP2008531560A (ja) 2008-08-14
AU2006217027A1 (en) 2006-08-31
WO2006091332A3 (en) 2006-11-16
CN101184499B (zh) 2012-03-28
CN101184499A (zh) 2008-05-21
CA2598666A1 (en) 2006-08-31
EP1853288A2 (en) 2007-11-14
US20060188496A1 (en) 2006-08-24
KR20070110087A (ko) 2007-11-15
HK1122723A1 (en) 2009-05-29
MX2007010244A (es) 2008-03-10
WO2006091332A2 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
BRPI0608309A2 (pt) administração intranasal de agentes ativos ao sistema nervoso central
WO2009058957A3 (en) Intranasal administration of active agents to the central nervous system
GB201201314D0 (en) Composition
EA201000211A1 (ru) Способ модулирования рецептора gpr119, сопряженного с g-белком, и используемые при этом соединения
BRPI0922789A2 (pt) peptídeo de ligação de albumina intermediador para reconhecimento de doença
EA201001204A1 (ru) Методы и композиции, в которых применяют слитые полипептиды klotho-fgf
WO2006015259A3 (en) Compounds and compositions as modulators of steroid hormone nuclear receptors
EP4276180A3 (en) Clostridium histolyticum enzyme
CO6290752A2 (es) Antagonistas n,n-disustituidos de aminoalquilbifenilo de receptores d2 de prostaglandina
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX2009002893A (es) Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap).
PE20170938A1 (es) Suministro al sistema nervioso central de agentes terapeuticos
EA200870185A1 (ru) Комбинации ингибиторов ang2 и vegf
PE20181790A1 (es) Metodos para tratar o prevenir trastornos relacionados con el colesterol
BRPI0510170B8 (pt) composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto
JO2576B1 (en) Antibodies
MY158560A (en) Composition comprising antiboby that binds to domain ii of her2 and acidic variants thereof
AR060786A1 (es) Variaciones cristalinas de (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
ATE314062T1 (de) Zusammensetzungen zur abgabe von cortisolantagonisten
WO2007134241A3 (en) Nasal delivery of therapeutic agents using tight junction agonists
EP2279244A4 (en) METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS
MX2008012748A (es) Un proceso para la concentracion de un polipeptido.
MX2008008413A (es) Composicion farmaceutica para el tratamiento de las enfermedades de las uñas.
WO2011057027A3 (en) Method for treating heart failure with stresscopin-like peptides

Legal Events

Date Code Title Description
B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: NAO CONHECIDA A PETICAO NO 046757/RJ DE 26/05/2010 EM VIRTUDE DO DISPOSTO NO ART. 219, INCISO II DA LPI. (QUANDO A PETICAO NAO APRESENTA FUNDAMENTACAO LEGAL)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2395 DE 29-11-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B15K Others concerning applications: alteration of classification

Ipc: A61K 38/34 (2006.01), A61K 9/00 (2006.01), A61K 47